-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The iron hoops for volume purchases are tightened.
If drugs enter volume purchases and are not selected, then sales in the hospital will become increasingly difficult and even related products will be removed from the hospital in disguise
.
The "Opinions of the General Office of the State Council on Promoting the Normalized and Institutionalized Development of Centralized and Volume Procurement of Drugs" clearly stated that the procurement volume should be determined reasonably
.
The agreed purchase amount is determined according to the purchase amount base and the agreed purchase ratio, and is disclosed in the purchase document
"Yes" means that it is also possible, that is, it can be used, or it can be used without it!
From 2019 to the present, the local quantity procurement policies are often based on the country.
It is agreed that 70%-80% of the stock will be used as the bargaining chip for quantity procurement.
The price is exchanged for the quantity.
The outcome of non-selected products is often not included in the quantity.
Purchasing products with the same generic name and route of administration can continue to be sold online, but in some places it will be slightly stricter, and all these drugs will be included in the monitoring and management, but the overall idea is that the purchase volume should not be higher than the previous year in principle The historical purchase volume shall not exceed the selected drug purchase volume
.
But changes in circumstances are often caught off guard
.
Recently, the industry's vigorous discussion about the circulated content of the Guangdong Inter-Provincial Volume Procurement Alliance shows that if the product is selected, medical institutions will continue to use the selected product in principle, and directly cut off the path of non-selected drugs
Moving forward, in March of this year, Fujian Province issued the official document of volume procurement, although it still followed the "Public medical institutions prioritize the use of selected varieties, and the remaining amount can be purchased in appropriate quantities and prices are suitable for other common names with the same common name.
" However, in order to prevent some companies from only wanting to operate margins and do not want to participate in speculative ideas of mass procurement, the three chapters of the stricter pre-arrangement are clearly proposed, namely, "Fujian Province has linked the Internet and meets the declaration requirements if they have not signed up to participate in the concentration.
with the amount of purchase, the provincial Medical Device joint procurement center will be involved in product related businesses hanging suspended, not hanging net sales in the province within the procurement cycle "
.
To be honest, winning or not winning the bid is a question of willingness and ability, while participation or not is a question of attitude.
Coincidentally, in the new round of GPO documents in Shanghai recently, the requirements for the procurement volume are intriguing: First, the public medical institutions (part of) the drug centralized bargaining procurement alliance drug group procurement and the centralized bargaining document alliance medical institutions give priority to the selection of selected drugs, and develop the substance Procurement is fully implemented through the Sunshine Platform
.
The procurement of unselected drugs by alliance medical institutions shall be reviewed and approved by the Medical Institution Pharmaceutical Affairs Management and Pharmacotherapy Committee
What does that mean? The attitude of the Shanghai GPO is that if the unselected drugs want to continue to be sold in Shanghai, they must be approved by the Hospital Pharmacy Board
.
But friends in the frontline of sales know that once the bidding period has passed, it means that the access to the hospital is basically blocked.
Besides, the stock part itself is not reserved for over-reviewed or deemed over-reviewed products.
If your product is just an over-reviewed or just a generic drug, then you just want to continue to play with the stock without participating in volume purchases, and at the same time, you want to continue to sell at high prices.
Not all varieties can go to the out-of-hospital pharmacy, nor are all varieties that have long-term variety accumulation for patient education.
